Key Points
-
Allogeneic bone-marrow transplantation is the best treatment for patients with haematological cancers. This procedure, however, is limited by lack of suitable donors, as well as the complications of graft-versus-host disease (GVHD) and opportunistic infection.
-
Umbilical-cord blood is an excellent source of haematopoietic stem cells. It has the advantages of speedy availability and reduced incidence of causing GVHD. This allows for transplantation of grafts with limited HLA disparity, and thereby extends the donor pool.
-
The main determinants of successful umbilical-cord blood transplant are the number of cells that are available for transplantation and HLA matching.
-
Cord blood transplantation has been validated as an alternative to bone-marrow transplantation for the treatment of leukaemia in children.
-
A number of approaches are being developed to improve the efficacy of cord blood transplantation in adults, such as multiple-unit transplantation and reduced intensity of chemo-radiation therapy.
Abstract
Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited by the lack of suitable bone-marrow donors, the risk of graft-versus-host disease (GVHD) and slow immune reconstitution. Umbilical-cord blood is an alternative source of haematopoietic stem cells that has recently been tested in both child and adult cancer patients. These studies have identified several advantages to umbilical-cord cell transplantation, including a lower incidence of GVHD. Umbilical-cord blood is therefore a promising alternative to bone-marrow-derived stem cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Broxmeyer, H. E. et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc. Natl Acad. Sci. USA 86, 3828–3832 (1989).
Broxmeyer, H. E. et al. Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. Blood Cells 17, 313–329 (1991).
Broxmeyer, H. E. et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc. Natl Acad. Sci. USA 89, 4109–4113 (1992).
Broxmeyer, H. E. & Cooper, S. High-efficiency recovery of immature haematopoietic progenitor cells with extensive proliferative capacity from human cord blood cryopreserved for 10 years. Clin. Exp. Immunol. 107 (Suppl. 1), 45–53 (1997).
Mayani, H. & Lansdorp, P. M. Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells 16, 153–165 (1998).
de Wynter, E. A., Emmerson, A. J. & Testa, N. G. Properties of peripheral blood and cord blood stem cells. Baillieres Best Pract Res Clin Haematol. 12, 1–17 (1999).
Leung, W., Ramirez, M., Novelli, E. M. & Civin, C. I. In vivo engraftment potential of clinical hematopoietic grafts. J. Investig. Med. 46, 303–311 (1998).
Lewis, I. & Verfaillie, C. M. Multi-lineage expansion potential of primitive hematopoietic progenitors. Superiority of umbilical cord blood compared to mobilized peripheral blood. Exp. Hematol. 28, 1087–1095 (2000).
Gluckman, E. et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N. Engl. J. Med. 321, 1174–1178 (1989).
Wagner, J. E. & Kurtzberg, J. in Cellular Characteristics of Cord Blood and Cord Blood Transplantation (ed. Broxmeyer, H. E.) 113–146 (AABB Press, Bethesda, Maryland, 1998).
Gluckman, E. et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N. Engl. J. Med. 337, 373–381 (1997).
Kurtzberg, J. et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N. Engl. J. Med. 335, 157–166 (1996).
Wagner, J. E. et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 88, 795–802 (1996).
Rubinstein, P. et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N. Engl. J. Med. 339, 1565–1577 (1998).
Rubinstein, P. & Stevens, C. E. Placental blood for bone marrow replacement: the New York Blood Center's program and clinical results. Baillieres Best Pract. Res. Clin. Haematol. 13, 565–584 (2000).
Barker, J. N. et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 97, 2957–2961 (2001).
Rocha, V. et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97, 2962–2971 (2001).
Wagner, J. E. et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100, 1611–1618 (2002).
Broxmeyer, H. in Cellular Characteristics of Cord Blood and Cord Blood Transplantation (ed. Broxmeyer, H.) 1–9 (AABB Press, Bethesda, Maryland, 1998).
Wagner, J. E., Kernan, N. A., Steinbuch, M., Broxmeyer, H. E. & Gluckman, E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 346, 214–219 (1995).
Rubinstein, P., Rosenfield, R. E., Adamson, J. W. & Steven, C. E. Stored placental blood for unrelated bone marrow reconstitution. Blood 81, 1679–1690 (1993).
Rubinstein, P. et al. Unrelated placental blood for bone marrow reconstitution: organization of the placental blood program. Blood Cells 20, 587–596 (1994).
Peterson, R., Clay, M. & McCullough, J. in Cellular Characteristics of Cord Blood and Cord Blood Transplantation (ed. Broxmeyer, H.) 165–197 (AABB Press, Bethesda, Maryland, 1998).
Gluckman, E. in Cellular Characteristics of Cord Blood and Cord Blood Transplantation (ed. Broxmeyer, H. E.) 147–164 (ASBB Press, Bethesda, Maryland, 1998).
Roncarolo, M. et al. in Cellular Charaterisitcs of Cord Blood and Cord Blood Transplantation (ed. Broxmeyer, H.) 67–81 (AABB Press, Bethesda, Maryland, 1998).
Rocha, V. et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. N. Engl. J. Med. 342, 1846–1854 (2000).
Rubinstein, P. et al. Graft selection in unrelated placental/umbilical cord blood (PCB) transplantation: influence and weight of HLA match and cell dose on engraftment and survival. Blood 96, A588 (2000).
Rubinstein, P. et al. Comparison of unrelated cord blood and unrelated bone marrow transplants for leukemia in children: a collaborative study of the New York Blood Center and the International Bone Marrow Transplant Registry. Blood 98, A814 (2001).
Barker, J. N. et al. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol. Blood Marrow Transplant. 8, 257–260 (2002).
Thomson, B. G. et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 96, 2703–2711 (2000).
Moretta, A. et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp. Hematol. 29, 371–379 (2001).
Talvensaari, K. et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 99, 1458–1464 (2002).
Klein, A. K. et al. T-Cell recovery in adults and children following umbilical cord blood transplantation. Biol. Blood Marrow Transplant. 7, 454–466 (2001).
Weinberg, K. et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 97, 1458–1466 (2001).
Barker, J. N. et al. Low incidence of Epstein–Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol. Blood Marrow Transplant. 7, 395–399 (2001).
Laughlin, M. J. et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N. Engl. J. Med. 344, 1815–1822 (2001).
Sierra, J. et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 26, 397–404 (2000).
Barker, J. N. et al. Determinants of survival after human leucocyte antigen matched unrelated donor bone marrow transplantation in adults. Br. J. Haematol. 118, 1–7 (2002).
Ballen, K. K. et al. Bigger is better: maternal and neonatal predictors of hematopoietic potential of umbilical cord blood units. Bone Marrow Transplant. 27, 7–14 (2001).
McNiece, I., Kubegov, D., Kerzic, P., Shpall, E. J. & Gross, S. Increased expansion and differentiation of cord blood products using a two-step expansion culture. Exp. Hematol. 28, 1181–1186 (2000).
Lewis, I. D. et al. Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system. Blood 97, 3441–3449 (2001).
McNiece, I. K., Almeida–Porada, G., Shpall, E. J. & Zanjani, E. Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long-term engrafting potential. Exp. Hematol. 30, 612–616 (2002).
Shpall, E. J. et al. Transplantation of ex vivo expanded cord blood. Biol. Blood Marrow Transplant. 8, 368–376 (2002).
MacMillan, M., Ramsey, N., Atkinson, K. & Wagner, J. Ex-vivo culture expanded parental haplo-identical mesenchymal stem cells (MSC) to promote engraftment in recipients of unrelated donor umbilical cord blood (UCB): results of a Phase I–II clinical trial. Blood 100, A836 (2002).
Barker, J., Weisdorf, D., Defor, T., McGlave, P. & Wagner, J. Multiple unit umbilical cord blood transplantation in high risk adults with hematologic malignancies: analysis of engraftment and chimerism. Blood 100, A41 (2002).
Wagner, J. E., Auerbach, A. D. & Kahn, J. Embryo selection to create a genotypic identical hematopoietic stem cell (HSC) donor for a child with fanconi anemia (FA): transplant outcome and ethical implications. Blood 98, A744 (2001).
Rizzieri, D. A. et al. Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood 98, 3486–3488 (2001).
Barker, J. N., Weisdorf, D. J., DeFor, T. E. & Wagner, J. E. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after non-myeloablative conditioning. Blood 100, A42 (2002).
Acknowledgements
Supported by grants from the National Institutes of Health and the Children's Cancer Research Fund.
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
DATABASES
Cancer.gov
LocusLink
OMIM
FURTHER INFORMATION
Cord blood-bank operating procedures
Glossary
- AUTOLOGOUS TISSUE
-
Haematopoietic stem cells that are derived from the patient.
- ALLOGENEIC TISSUE
-
Haematopoietic stem cells that are from an antigenically distinct individual of the same species — from a sibling or unrelated donor.
- GRAFT-VERSUS-LEUKAEMIA (GVL) EFFECT
-
The ability of the immune cells that are derived from transplanted haematopoietic stem cells to recognize and destroy leukaemia cells. This partially accounts for the mechanism of action of allogeneic transplantation as treatment for leukaemia. The term has been broadened to 'graft-versus-malignancy', to acknowledge that this effect is seen in patients with non-leukaemic diseases, such as myeloma or lymphoma.
- GRAFT-VERSUS-HOST DISEASE (GVHD).
-
A complication of allogeneic haematopoietic transplantation. It occurs when the immune system of the donor graft recognizes the tissues of the recipient (host) as foreign and attacks them. This can be lethal in its most severe form.
- MAJOR HISTOCOMPATIBILITY ANTIGENS
-
Antigens that are encoded by genes in the major histocompatibility complex on the short arm of chromosome 6. They are highly polymorphic and determine the immunological identity of the cell. In humans, they are also known as human leukocyte antigens (HLAs).
- CLASS 1 MATCHING
-
Matching patients for HLA-A and HLA-B antigens.
- MYELOABLATIVE
-
High-dose chemotherapy or chemotherapy with radiation that destroys (ablates) the haematopoietic system of the patient.
- CD34+ CELLS
-
Immature haematopoietic progenitors.
- TRANSPLANT-RELATED MORTALITY
-
Death due to transplant complications such as GVHD or infection (in contrast to death from relapse of leukaemia). Also known as 'non-relapse mortality'.
- EVENT-FREE SURVIVAL
-
The length of time after treatment that a person remains free of certain negative events, such as severe treatment side effects, cancer recurrence or progression, or death (from treatment side effects or from the cancer itself).
- PRE-IMPLANTATION GENETIC DIAGNOSIS
-
The technique of testing for certain diseases or other attributes, such as HLA type, in an embryo.
Rights and permissions
About this article
Cite this article
Barker, J., Wagner, J. Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 3, 526–532 (2003). https://doi.org/10.1038/nrc1125
Issue Date:
DOI: https://doi.org/10.1038/nrc1125
This article is cited by
-
Reconstruction of bone marrow microenvironment for expansion of hematopoietic stem cells by a histone deacetylase inhibitor
Cytotechnology (2023)
-
Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation
International Journal of Hematology (2023)
-
Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment
Annals of Hematology (2019)
-
Isolation and characterization of ovine umbilical cord-derived mesenchymal stem cells
Cytotechnology (2019)
-
Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform
Molecular Therapy (2016)